Cellectis S.A. Reports Results from Annual General Meeting Held on June 26, 2017
June 26 2017 - 4:30PM
Business Wire
Regulatory News:
Cellectis S.A. (Paris:ALCLS) (NASDAQ:CLLS) Shareholders’
General Meeting (Alternext: ALCLS - Nasdaq: CLLS) was held on
Monday, June 26, 2017 in Paris, at its head office.
At the meeting, during which more than 73% of voting rights were
exercised, all the resolutions for which the management recommended
a vote in favor, were adopted.
The resolutions adopted by Cellectis' shareholders included:
- Appointment of two new directors to the
board of directors, Mr Rainer Boehm and Mr Hervé Hoppenot;
- Renewal of the term of office of
Director of Mr Laurent Arthaud, Mr Pierre Bastid and Mrs
Annick Schwebig;
- Approval of the annual financial
statements for the financial year ended December 31, 2016;
- Approval of the consolidated financial
statements for the financial year ended December 31, 2016.
The full results of the vote can be examined on the company’s
website
https://www.cellectis.com/en/investors/general-meetings/.
About Cellectis
Cellectis is a clinical-stage biopharmaceutical company focused
on developing a new generation of cancer immunotherapies based on
gene-edited T-cells (UCART). By capitalizing on its 17 years of
expertise in gene editing – built on its flagship TALEN® technology
and pioneering electroporation system PulseAgile – Cellectis uses
the power of the immune system to target and eradicate cancer
cells.
Using its life-science-focused, pioneering genome engineering
technologies, Cellectis’ goal is to create innovative products in
multiple fields and with various target markets.
Cellectis is listed on the Nasdaq market (ticker: CLLS) and on
the NYSE Alternext market (ticker: ALCLS). To find out more about
us, visit our website: www.cellectis.com.
Talking about gene editing? We do it. TALEN® is a registered
trademark owned by the Cellectis Group.
Disclaimer
This press release and the information contained herein do not
constitute an offer to sell or subscribe, or a solicitation of an
offer to buy or subscribe, for shares in Cellectis in any country.
This press release contains forward-looking statements that relate
to the Company’s objectives based on the current expectations and
assumptions of the Company’s management only and involve risk and
uncertainties that could cause the Company to fail to achieve the
objectives expressed by the forward-looking statements above.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170626006181/en/
Cellectis S.A.Media:Jennifer Moore, 917-580-1088VP
of Communicationsmedia@cellectis.comorCaitlin Kasunich,
212-896-1241KCSA Strategic
Communicationsckasunich@kcsa.comorIR:Simon Harnest,
646-385-9008VP of Corporate Strategy and
Financesimon.harnest@cellectis.com
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Apr 2023 to Apr 2024